RT Journal Article
T1 Analysis of the Differences in Ocular Surface Damage and Inflammatory Signs between Healthy and Evaporative Dry Eye Participants
A1 García Queiruga, Jacobo
A1 Pena Verdeal, Hugo
A1 Sabucedo Villamarín, Belén
A1 García Resúa, Carlos
A1 Giráldez Fernández, María Jesús
A1 Yebra-Pimentel Vilar, Eva
K1 Conjunctival hyperemia
K1 Corneal staining
K1 Evaporative dry eye
K1 Meibography
K1 Meibomian gland loss area
AB Objective: Distinguish between EDE severity levels by analysing the MGLA, conjunctival hyperemia and corneal staining.Methods: One hundred participants were recruited based on OSDI, TO, TFBUT, TMH, and LLP to be categorised as healthy (Group 1) or EDE (Group 2). Group 2 was divided into Group 2A (mild symptoms), 2B (moderate), and 2C (severe). MGLA, conjunctival hyperemia, and corneal staining were measured.Results: Positive correlation between MGLA, conjunctival hyperemia, and corneal staining were found (all r ≥ 0.221, p ≤ 0.027). Significant differences were found: MGLA between Group 1 vs. 2C and 2C vs. 2A or 2B; conjunctival hyperemia between Group 1 vs. 2A, 2B or 2C; corneal staining between Group 1 vs. 2B or 2C and 2A vs. 2B or 2C (all p ≤ 0.049).Conclusion: Severe EDE participants have higher MGLA, conjunctival hyperemia, and corneal staining values than healthy, mild, or moderate EDE participants.
PB Taylor and Francis
SN 0927-3948
YR 2023
FD 2023-05-19
LK http://hdl.handle.net/10347/32142
UL http://hdl.handle.net/10347/32142
LA eng
NO Jacobo Garcia-Queiruga , Hugo Pena-Verdeal , Belén Sabucedo-Villamarin , Carlos Garcia-Resua , Maria J. Giraldez & Eva Yebra-Pimentel (2023) Analysis of the Differences in Ocular Surface Damage and Inflammatory Signs between Healthy and Evaporative Dry Eye Participants, Ocular Immunology and Inflammation, 31:5, 970-977, DOI: 10.1080/09273948.2022.2075398
NO This is an Accepted Manuscript of an article published by Taylor & Francis in "Ocular Immunology and Inflammation" on 2022/05/19, available at: https://doi.org/10.1080/09273948.2022.2075398
DS Minerva
RD 28 abr 2026